skip navigation

Skip Nav

HIV/AIDS Clinical Trials

Clinical Trial Search Results

43 studies were found about ( tipranavir OR Aptivus )

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

Condition: HIV Infections

NCT ID: NCT00062660

Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children

Condition: HIV Infections

NCT ID: NCT00076999

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV

Condition: HIV Infections

NCT ID: NCT00307502

Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.

Condition: HIV Infections

NCT ID: NCT00531206

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

Condition: HIV Infections

NCT ID: NCT00146328

Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents

Condition: HIV Infections

NCT ID: NCT00207948

Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours

Condition: HIV Infections

NCT ID: NCT00607958

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

Condition: HIV Infections

NCT ID: NCT00440271

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

Condition: HIV Infections

NCT ID: NCT00097799

A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Condition: HIV Infections

NCT ID: NCT00976950

Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options

Condition: HIV Infections

NCT ID: NCT00144287

Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation

Condition: HIV Infections

NCT ID: NCT00447902

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

Condition: HIV Infections

NCT ID: NCT00933205

Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-Term Observational Study

Condition: HIV Infections

NCT ID: NCT00537966

Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals

Condition: HIV Infections

NCT ID: NCT00034866

Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir

Condition: HIV Infections

NCT ID: NCT00486330

Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

Condition: HIV Infections

NCT ID: NCT00144170

Surveillance Cohort Long-Term Toxicity Antiretrovirals in HIV-Infected Patients Enrolled in TPV Cohort

Condition: HIV Infections

NCT ID: NCT00805857

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

Condition: HIV Infections

NCT ID: NCT00056641

Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)

Condition: HIV Infections

NCT ID: NCT00615563

Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients

Condition: HIV Infections

NCT ID: NCT00530920

Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects

Condition: HIV Infections

NCT ID: NCT00344123

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers

Condition: HIV Infections

NCT ID: NCT01068925

Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

Condition: HIV Infection

NCT ID: NCT00352066

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Condition: HIV-Associated Lipodystrophy Syndrome; Cardiovascular Disease

NCT ID: NCT00192660

Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients

Condition: HIV Infections

NCT ID: NCT00294372

Optimizing Treatment for Treatment-Experienced, HIV-infected People

Condition: HIV Infections

NCT ID: NCT00537394

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

Condition: HIV Infections

NCT ID: NCT00054717

Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy

Condition: HIV Infections

NCT ID: NCT00615290

3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study

Condition: HIV Infections

NCT ID: NCT00275444

Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

Condition: HIV Infections

NCT ID: NCT00517192

A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

Condition: HIV Infections

NCT ID: NCT00144105

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

Condition: HIV Infection

NCT ID: NCT00735072

Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

Condition: ADHD; HIV

NCT ID: NCT01232361

Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

Condition: Human Immunodeficiency Virus

NCT ID: NCT01814722

Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

Condition: HIV; HIV Infections

NCT ID: NCT00966329

Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product

Condition: HIV Infections

NCT ID: NCT00773708

Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children

Condition: This Study is Designed to Collect Treatment Data of Thai Children on Third Line ARV Therapy.

NCT ID: NCT01225406

Two Part Study to Study Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir (EVG) Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Subjects

Condition: Acquired Immune Deficiency Syndrome (AIDS); HIV Infections

NCT ID: NCT01923311

Clinical Trial of CNS-targeted HAART (CIT2)

Condition: HIV Infections

NCT ID: NCT00624195

Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)

Condition: HIV Infection

NCT ID: NCT00707733

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Condition: HIV Infections

NCT ID: NCT00042289

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

Condition: Kaposi's Sarcoma

NCT ID: NCT01276236